Search Results - "Suda, Goki"

Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poorer Prognosis in Patients With Non‐HBV‐Related HCC—Authors' Reply.

Authors: Yasuura, Naohiro Suda, Goki Ohara, Masatsugu et al.

Source: Alimentary Pharmacology & Therapeutics. Dec2024, Vol. 60 Issue 11/12, p1647-1649. 3p.

Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohort.

Authors: Suda, Goki Baba, Masaru Yamamoto, Yoshiya et al.

Source: Scientific Reports. 11/28/2025, Vol. 15 Issue 1, p1-7. 7p.

Cirrhotic Cardiomyopathy: Prevalence and Clinical Impact on Liver Cirrhosis Outcomes.

Authors: Kitagataya, Takashi Suda, Goki Tanaka, Takatsugu et al.

Source: Hepatology Research. Oct2025, Vol. 55 Issue 10, p1367-1375. 9p.

Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective study.

Authors: Yang, Zijian Suda, Goki Sho, Takuya et al.

Source: Hepatology Research. Mar2025, Vol. 55 Issue 3, p433-443. 11p.

Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC.

Authors: Yasuura, Naohiro Suda, Goki Ohara, Masatsugu et al.

Source: Alimentary Pharmacology & Therapeutics. Nov2024, Vol. 60 Issue 10, p1315-1324. 10p.

Cachexia is an independent predictor of mortality in patients with cirrhosis.

Authors: Miwa, Takao Suda, Goki Tateishi, Ryosuke et al.

Source: Hepatology Research. Jun2025, Vol. 55 Issue 6, p859-867. 9p.

Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan.

Authors: Sasaki, Takashi Suda, Goki Ohara, Masatsugu et al.

Source: Hepatology Research. Oct2023, Vol. 53 Issue 10, p960-967. 8p.

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy.

Authors: Kawagishi, Naoki Suda, Goki Sakamori, Ryotaro et al.

Source: Scientific Reports. 10/7/2022, Vol. 12 Issue 1, p1-11. 11p.

Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight.

Authors: Tokuchi, Yoshimasa Suda, Goki Kawagishi, Naoki et al.

Source: Hepatology Research. Jul2023, Vol. 53 Issue 7, p595-606. 12p.

Time‐dependent changes in the seroprevalence of COVID‐19 in asymptomatic liver disease outpatients in an area in Japan undergoing a second wave of COVID‐19.

Authors: Suda, Goki Ogawa, Koji Kimura, Megumi et al.

Source: Hepatology Research. Oct2020, Vol. 50 Issue 10, p1196-1200. 5p.

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals.

Authors: Tokuchi, Yoshimasa Suda, Goki Kimura, Megumi et al.

Source: Scientific Reports. 8/16/2021, Vol. 11 Issue 1, p1-9. 9p.

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma.

Authors: Kohya, Risako Suda, Goki Ohara, Masatsugu et al.

Source: Cancers. Jun2023, Vol. 15 Issue 12, p3257. 15p.

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.

Authors: Yang, Zijian Suda, Goki Maehara, Osamu et al.

Source: Cancers. Feb2023, Vol. 15 Issue 3, p593. 14p.

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C.

Authors: Kawagishi, Naoki Suda, Goki Yamamoto, Yoshiya et al.

Source: Viruses (1999-4915). Jan2023, Vol. 15 Issue 1, p181. 12p.

Overestimated renal function in patients with liver cirrhosis predicts poor prognosis.

Authors: Yoshida, Sonoe Suda, Goki Ohara, Masatsugu et al.

Source: Hepatology Research. Jul2022, Vol. 52 Issue 7, p603-613. 11p.

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B.

Authors: Suzuki, Kazuharu Suda, Goki Yamamoto, Yoshiya et al.

Source: PLoS ONE. 1/20/2022, Vol. 17 Issue 1, p1-14. 14p.

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria.

Authors: Sho, Takuya Suda, Goki Ogawa, Koji et al.

Source: Hepatology Research. Sep2021, Vol. 51 Issue 9, p979-989. 11p.

Featured Cover.

Authors: Kumazaki, Shusuke Hikita, Hayato Tahata, Yuki et al.

Source: Alimentary Pharmacology & Therapeutics. Aug2024, Vol. 60 Issue 3, pi-i. 1p.

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C.

Authors: Kawagishi, Naoki Suda, Goki Kimura, Megumi et al.

Source: Scientific Reports. 4/28/2021, Vol. 11 Issue 1, p1-9. 9p.

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report.

Authors: Umemura, Machiko Suda, Goki Tsukamoto, Shihori et al.

Source: BMC Infectious Diseases. 4/27/2021, Vol. 21 Issue 1, p1-5. 5p.